logo-loader
Clinigen Group PLC

Clinigen Group appoints Nick Keher as new CFO

Keher has previously headed up Royal Bank of Canada’s European healthcare equity research team, while he has also held roles at GSK and Lloyd’s Pharmacy

pills
Keher is replacing Martin Abell, who has been Clinigen’s CFO since 2015

Pharma services company Clinigen Group PLC (LON:CLIN) has appointed Nick Keher as its new chief financial officer.

Keher, who is set to take up his new role on 19 March, joins from Canadian investment bank Royal Bank of Canada, where he was a managing director and head of the European healthcare equity research team.

READ: Clinigen to report sharp jump in revenue and profit

He is replacing the outgoing Martin Abell who has resigned and is due to leave a couple of weeks after Keher’s arrival.

“Nick brings considerable pharmacy and pharmaceutical experience as well as financial expertise, both as an accountant and from working in the financial markets,” said chief executive Shaun Chilton.

“He has a deep knowledge and insight of our business through his research and analysis of Clinigen since its IPO in 2012. He will be a key addition to the executive management team.”

Clinigen shares were down 2.1% to 794p in late morning trading on Tuesday.

Quick facts: Clinigen Group PLC

Price: £9.11

Market: AIM
Market Cap: £1.21 billion
Follow

Watch

Clinigen Group says acquisitions fueling expected profit growth in its...

Clinigen Group PLC (LON:CLIN) Head of Investor Relations Matthew Parrish tells Proactive Investors the company's recent trading update indicates that profits at the pharma services company are expected to have soared by more than a third when it reports its full-year results in...

4 weeks, 2 days ago

2 min read

;